We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-8.74%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.37B
AUM Growth
-$222M
Cap. Flow
+$343M
Cap. Flow %
14.48%
Top 10 Hldgs %
48.21%
Holding
122
New
26
Increased
34
Reduced
9
Closed
19

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$66.1M
2
BDTX icon
Black Diamond Therapeutics
BDTX
+$51.6M
3
SDGR icon
Schrodinger
SDGR
+$33.9M
4
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$30.5M
5
PYPL icon
PayPal
PYPL
+$26.5M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$37M
2
XNCR icon
Xencor
XNCR
+$18.9M
3
BNTX icon
BioNTech
BNTX
+$15.6M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$11M
5
BABA icon
Alibaba
BABA
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 69.42%
2 Consumer Discretionary 14.34%
3 Miscellaneous 11.65%
4 Financials 1.8%
5 Technology 1.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRIS icon
101
Curis
CRIS
$2.72M
$1.06M 0.04%
3,750
– –
RIGL icon
102
Rigel Pharmaceuticals
RIGL
$847M
$546K 0.02%
+35,000
New +$745K
CYPH
103
Cypherpunk Technologies Inc
CYPH
$278M
$395K 0.02%
+25,000
New +$484K
DOYU
104
DouYu International Holdings
DOYU
$142M
– –
-40,000
Closed -$3.39M
FATE icon
105
CALL
Fate Therapeutics
FATE
$277M
– –
-200,000
Closed -$3.91M
IGMS
106
DELISTED
IGM Biosciences
IGMS
– –
-150,000
Closed -$5.72M
INCY icon
107
CALL
Incyte
INCY
$24.8B
– –
-100,000
Closed -$8.73M
MRNA icon
108
CALL
Moderna
MRNA
$58.6B
– –
-500,000
Closed -$9.78M
MS icon
109
CALL
Morgan Stanley
MS
$324B
– –
-2,000,000
Closed -$102M
NIO icon
110
CALL
NIO
NIO
$9.2B
– –
-1,750,000
Closed -$7.04M
NKTR icon
111
CALL
Nektar Therapeutics
NKTR
$2.34B
– –
-33,333
Closed -$10.8M
NTLA icon
112
Intellia Therapeutics
NTLA
$1.66B
– –
-199,700
Closed -$2.93M
REAL icon
113
The RealReal
REAL
$1.19B
– –
-200,000
Closed -$3.77M
SGMO
114
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-405,000
Closed -$3.39M
TWST icon
115
Twist Bioscience
TWST
$8.93B
– –
-100,000
Closed -$2.1M
VKTX icon
116
Viking Therapeutics
VKTX
$3.68B
– –
-350,000
Closed -$2.81M
XNCR icon
117
Xencor
XNCR
$1.81B
– –
-550,000
Closed -$18.9M
LGF.A
118
CALL
DELISTED
Lions Gate Entertainment Corp. Class A Voting Shares
LGF.A
– –
-500,000
Closed -$5.33M
KRTX
119
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-50,000
Closed -$3.77M
RETA
120
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-50,000
Closed -$10.2M
DRNA
121
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-500,000
Closed -$11M
STML
122
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-360,000
Closed -$3.83M
1 2 3 4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q1 2020 Portfolio in Review

As of Q1 2020, Artal Group held 122 positions worth $2.37B, down 8.6% from $2.59B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group deployed $343M of net new capital in Q1 2020, opening 26 new positions and adding to 34 existing holdings. Its largest new stake was uniQure: 1,150,000 shares worth $54.6M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 63% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

On the sell side, the largest reduction was Moderna, an estimated $37M trimmed.

  • Artal Group's largest Q1 2020 buy was uniQure: 1,150,000 shares worth $54.6M.
  • Artal Group added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q1 2020, an estimated $30.5M increase.
  • Artal Group's biggest Q1 2020 reduction was Moderna, cutting an estimated $37M.
  • Artal Group fully exited Xencor in Q1 2020, selling an estimated $18.9M.
  • Artal Group's ten largest holdings make up 48% of its $2.37B portfolio in Q1 2020.
  • Artal Group opened 26 new positions and closed 19 in Q1 2020.
  • Artal Group's portfolio value fell 8.6% quarter-over-quarter to $2.37B.

Based on Artal Group's 13F filing for Q1 2020, filed 14 May 2020.